{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:45:13Z","timestamp":1792856713233,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Charles University, First Faculty of Medicine","award":["PROGRES Q25\/LF1"],"award-info":[{"award-number":["PROGRES Q25\/LF1"]}]},{"name":"Charles University, First Faculty of Medicine","award":["00064165"],"award-info":[{"award-number":["00064165"]}]},{"name":"Ministry of Health, Czech Republic, Research organization","award":["PROGRES Q25\/LF1"],"award-info":[{"award-number":["PROGRES Q25\/LF1"]}]},{"name":"Ministry of Health, Czech Republic, Research organization","award":["00064165"],"award-info":[{"award-number":["00064165"]}]},{"name":"General University Hospital in Prague","award":["PROGRES Q25\/LF1"],"award-info":[{"award-number":["PROGRES Q25\/LF1"]}]},{"name":"General University Hospital in Prague","award":["00064165"],"award-info":[{"award-number":["00064165"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alport syndrome (AS) is a hereditary kidney disease caused by pathogenic variants in COL4A3 and COL4A4 genes with autosomal recessive or autosomal dominant transmission or in the COL4A5 gene with X-linked inheritance. Digenic inheritance was also described. Clinically it is associated with microscopic hematuria, followed by proteinuria and chronic renal insufficiency with end-stage renal disease in young adults. Nowadays, there is no curative treatment available. The inhibitors of RAS (renin-angiotensin system) since childhood slow the progression of the disease. Sodium-glucose cotransporter-2 inhibitors seem to be promising drugs from DAPA-CKD (dapagliflozin\u2013chronic kidney disease) study, but only a limited number of patients with Alport syndrome was included. Endothelin type A receptor and angiotensin II type 1 receptor combined inhibitors, and lipid-lowering agents are used in ongoing studies in patients with AS and focal segmental glomerulosclerosis (FSGS). Hydroxychloroquine in AS is studied in a clinical trial in China. Molecular genetic diagnosis of AS is crucial not only for prognosis prediction but also for future therapeutic options. Different types of mutations will require various types of gene, RNA, or protein therapy to improve the function, the of final protein product.<\/jats:p>","DOI":"10.3390\/ijms24065522","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:29:16Z","timestamp":1678764556000},"page":"5522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Current and Future Therapeutical Options in Alport Syndrome"],"prefix":"10.3390","volume":"24","author":[{"given":"Jana","family":"Reiterov\u00e1","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic"},{"name":"First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-0689","authenticated-orcid":false,"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Sundaramoorthy, MAlport\u00b4s syndrome, Goodpasure\u00b4s syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1681\/ASN.2008101086","article-title":"Cellular origins of type IV collagen networks in developing glomeruli","volume":"20","author":"Abrahamson","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Genomics england research consortium. prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.kint.2020.03.031","article-title":"Genetic testing for kidney disease of unknown etiology","volume":"98","author":"Hays","year":"2020","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-011-1836-7","article-title":"Women and Alport syndrome","volume":"27","author":"Rheault","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: A unified classification of genetic disorders of collagen IV \u03b1345: A position paper of the Alport syndrome classification working group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int."},{"key":"ref_7","first-page":"2273","article-title":"Digenic Alport syndrome","volume":"8","author":"Savige","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfv325","article-title":"Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis","volume":"31","author":"Gast","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","article-title":"X-linked Alport syndrome: Natural history and genotype-phenotype correlations in girls and women belonging to 195 families","volume":"14","author":"Jais","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1681\/ASN.2012100985","article-title":"COL4A3\/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome","volume":"24","author":"Storey","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ajpath.2015.01.021","article-title":"Characterization of the intrarenal renin-angiotensin system in experimental Alport syndrome","volume":"185","author":"Bae","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/436046","article-title":"Safety and efficacy of the ACE-inhibitor Ramipril in Alport syndrome: The double-blind, randomized, placebo-controlled, multicentric phase III EARLY PRO-TECT Alport trial in pediatric patienst","volume":"2012","author":"Gross","year":"2012","journal-title":"ISRN Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00467-012-2372-9","article-title":"Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrom","volume":"28","author":"Webb","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ki.2011.452","article-title":"Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations","volume":"81","author":"Temme","year":"2012","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/HYPERTENSIONAHA.121.18360","article-title":"Mineralocorticoid receptor antagonist use and hard renal outcomes in real-world patients with chronic kidney disease","volume":"79","author":"Oka","year":"2022","journal-title":"Hypertension"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rubel, D., Zhang, Y., Sowa, N., Girbert, R., and Gross, O. (2021). Organoprotective effects of spironolactone on top of ramipril therapy in a mouse model for Alport syndrome. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132958"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendation for the diagnosis and management of Alport syndrome in children, adolescents, and yound adults-un update","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatric. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kideny disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ekir.2021.12.019","article-title":"Efficacy and safety of dapagliflozin in children with inherited proteinuric kidney disease: A pilot study","volume":"7","author":"Liu","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.ekir.2022.06.017","article-title":"Efficacy of dapagliflozin in adult autosomal recessive Alport syndrome","volume":"7","author":"Song","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1038\/s41598-021-86109-1","article-title":"Metformin ameliorates the severtiy of experimental Alport syndrome","volume":"11","author":"Omachi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.amjms.2022.01.026","article-title":"Relationship between metformin use and lactic acidosis in advanced chronic kidney disease: The REMIND-TMU study","volume":"364","author":"Chen","year":"2022","journal-title":"Am. J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/BST20150014","article-title":"Dissecting molecular cross-talk between Nrf2 and NF-\u0138 response pathways","volume":"43","author":"Wardyn","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-\u0138B inflammation and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"Akizawa","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2215\/CJN.02400222","article-title":"Effects of Bardoxolone methyl in Alport syndrome","volume":"17","author":"Warady","year":"2022","journal-title":"CJASN"},{"key":"ref_31","first-page":"23","article-title":"The dual ETAR\/ATR1 blocker sparsentan slows renal disease, improves lifespan and attenuates hearing loss in Alport mice:comparison with losartan","volume":"35","author":"Dominic","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rubel, D., Boulanger, J., Craciun, F., Xu, E.Y., Zhang, Y., Phillips, L., Callahan, M., Weber, W., Song, W., and Ngai, N. (2022). Anti-microRNA-21 therapy on top ACE inhibition delays renal failure in Alport syndrome mouse models. Cells, 11.","DOI":"10.3390\/cells11040594"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bbalip.2009.10.006","article-title":"Lipid homeostasis, lipotoxicity and the metabolic syndrome","volume":"1801","author":"Unger","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fendo.2014.00169","article-title":"Metabolism energetics and lipid biology in the podocyte\u2013cellular cholesterol-mediated glomerular injury","volume":"5","author":"Merscher","year":"2014","journal-title":"Front. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/ndt\/gfl810","article-title":"Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome","volume":"22","author":"Koepke","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1172\/JCI85939","article-title":"Local TNF causes NFAc1-dependent cholesterol-mediated podocyte injury","volume":"126","author":"Pedigo","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Weng, M., Lin, J., Chen, Y., Zhang, X., Zou, Z., Chen, Y., Cui, J., Fu, B., Li, G., and Chen, C. (2022). Time-averaged hematuria as a prognostic indicator of renal outcome in patients with IgA nephropathy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11226785"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effect of hydroxychloroquine on proteinuria in IGA nephropathy: A randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1073\/pnas.0601436103","article-title":"Bone-marrow-derived stem cell repair basement membrane collagen defects and reverse genetic kidney disease","volume":"103","author":"Sugimoto","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.ki.5001521","article-title":"Multipotenst mesenchymal stem cells reduce interstitial fibrosis but do not delay progressiion of chronic kidney disease in collagen4A3-deficient mice","volume":"70","author":"Ninichuk","year":"2006","journal-title":"Kidney Int."},{"key":"ref_43","first-page":"103891","article-title":"Aminoglyco-side-induced premature termination codon readthrough of COL4A5 nonsense mutations that cause Alport syndrome","volume":"25","author":"Omachi","year":"2021","journal-title":"BiorXiv"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Savige, J., Storey, H., Cheong, H., Gyiung Kang, H., Park, E., Hilbert, P., Persikov, A., Torres-Fernandez, C., Ars, E., and Torra, R. (2016). X-linked and autosomal recessive alport syndrome: Pathogenic variant features and further genotype-phenotype correlations. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161802"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u00b4s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ekir.2017.03.004","article-title":"The chemical chaperone, PBA, reduces ER stress and autophagy and increases collagen IV alpha5 expression in cultured fibroblasts from men with x-linked Alport syndrome and missense mutations","volume":"2","author":"Wang","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/hmg\/ddy369","article-title":"4-sodium phenyl butyric acid has both efficacy and counter-indicative effect in the treatment of Col4a1 disease","volume":"28","author":"Jones","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1681\/ASN.2017060690","article-title":"Laminin-521 protein therapy for glomerular basement membrane and podocyte abnormalities in a model of Pierson Syndrome","volume":"29","author":"Lin","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1681\/ASN.2013070798","article-title":"Feasibility of repairing glomerular basement membrane defects in Alport syndrome","volume":"25","author":"Lin","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41431-019-0537-8","article-title":"New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells","volume":"28","author":"Daga","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2016.08.009","article-title":"Single-Cell RNA-Seq reveals lineage and x chromosome dynamics in human preimplantation embryos","volume":"167","author":"Petropoules","year":"2016","journal-title":"Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:54:29Z","timestamp":1760122469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065522"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065522","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}